课题基金 / 基金详情

Dissecting cell surface protein diversity to enhance leptospiral vaccine efficacy.

Dissecting cell surface protein diversity to enhance leptospiral vaccine efficacy.
剖析细胞表面蛋白质多样性以增强钩端螺旋体疫苗的功效。
批准号:
BB/W016133/1
负责人:
Nicholas Evans
金额:
$93.91万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --

项目摘要

项目成果

Nicholas Evans的其他基金

相似基金

相关文献

中文摘要
翻译
钩端螺旋体病由钩端螺旋体细菌引起,是一种世界性的严重传染病,影响包括牛、狗和人在内的几种不同宿主物种。在全球范围内,牛深受其害,导致严重的经济损失、粮食安全降低、大量使用抗菌剂以及动物传人(人畜共患病)。英国的经济成本为2230万GB/年,热带地区的成本预计要高得多,包括许多低收入到中等收入国家(LMIC),因为更大的疾病负担和更严重的疾病。目前的牛钩端螺旋体病(BL)疫苗的特异性范围有限,需要冷链运输和储存,这在许多热带地区存在问题,通常是LMIC地区,疾病负担最大。使疫苗具有更广泛的保护性和更容易获得将增加全球的接种量,减少全球抗生素的使用和抗菌素耐药性的发展。这对钩端螺旋体病尤其重要。钩端螺旋体病被认为是在全球范围内出现/重新出现的,其驱动因素是全球变暖和洪水等极端气候事件的相关增加。细菌表面蛋白被认为是针对一系列钩端螺旋体物种和血清型提供交叉保护和持久免疫的重要靶点。钩端螺旋体的免疫逃避被认为是这些细菌用宿主分子包裹自己。虽然参与疾病的不同钩端螺旋体细菌是不同的,但它们必须具有几乎相同的免疫逃避机制,这种免疫逃避必须存在于细菌表面,以允许宿主结合和/或损害,因此是理想的疫苗靶标。因此,关键细菌表面蛋白的特征,特别是那些参与免疫逃避的蛋白,并确定它们的相互作用机制,应该有助于开发新的疫苗或疗法。最近的研究,通过突变细菌表面蛋白来防止宿主分子的结合,以及增强蛋白质的稳定性,提高了这些细菌成分用作疫苗时的保护能力。这种新的蛋白质工程的应用已经应用于一种重要的人类病原体疫苗的开发过程中,该疫苗现已获得许可,现在可以应用于兽医病原体。在这里,我们结合合成生物学、人工智能和生物信息学的方法来指导关键细胞表面蛋白的工程设计,以开发一种新型的耐热疫苗,具有广泛的钩端螺旋体特异性和增强的有效性。本研究将1)调查不同钩端螺旋体物种的候选疫苗的多样性,包括调查某些物种的变体是否表现出对特定宿主物种的分子的黏附偏好,从而导致已知的宿主特异性,并确定来自共生(无害)亲属的变体是否缺乏附着宿主分子的能力,2)将序列多样性/保守性和粘附力的差异与人工智能(AI)生成的结构模型与计算机方法一起使用来设计表面蛋白以限制宿主之间的相互作用,这与最近的人类病原体疾病工作相一致应允许更有效的疫苗,3)将序列多样性与AI生成的结构模型一起使用并在计算机方法中合成具有增强稳定性的表面蛋白,4)使用啮齿动物模型来识别最可能提供对一系列致病细菌的保护的工程细菌表面蛋白。通过上述各种和综合的方法调查BL疫苗候选,应有助于表征致病细菌,提高对疾病的理解,实质性地推进疫苗开发流水线和/或确定新的治疗方法。这种研究既及时又非常需要,以便能够预防甚至根除这一严重、重要的全球疾病。
英文摘要
Leptospirosis, caused by Leptospira bacteria, is a worldwide, severe infectious disease affecting several different host species including cattle, dogs and man. Globally, cattle are greatly afflicted resulting in severe economic losses, reduced food security, substantial antimicrobial use and animal to man (zoonotic) transmission. Economic cost to the UK is £22.3 million/year with much greater costs expected for tropical regions, including many low to middle income countries (LMICs), due to substantially greater disease burden and more severe disease. Current bovine leptospirosis (BL) vaccines have a limited range of specificity and require cold chain transport and storage, which is problematic in the many tropical, frequently LMIC regions with greatest disease burden. Making vaccines more broadly protective and easily accessible will increase uptake globally, decreasing global antibiotic use and antimicrobial resistance development. This is especially important for leptospirosis which is considered to be emerging/re-emerging globally and being driven by global warming and associated increases in extreme climatic events, such as flooding. Bacterial surface proteins are considered important targets to provide cross-protective and long lasting immunity against a range of Leptospira species and serovars. Immune evasion by leptospires, is considered to involve these bacteria coating themselves with host molecules. Whilst the different leptospire bacteria involved in disease are diverse, they must have near identical machinery for this immune evasion which must be present on the bacterial surface to allow for host binding and/or damage and therefore represent ideal vaccine targets. Thus, characterisation of key bacterial surface proteins, especially those involved in immune evasion and determining their mechanism of interaction should allow for development of novel vaccines or therapeutics. Recent research, mutating bacterial surface proteins to prevent binding of host molecules, as well as enhancing protein stability, has increased the protective ability of these bacterial components when used as vaccines. The application of such novel protein engineering has been used in the development pathway for an important human pathogen vaccine which is now licensed and can now be applied to veterinary pathogens. Here, we combine synthetic biology, artificial intelligence and in silico (bioinformatic) approaches to guide engineering of key cell surface proteins to develop a novel thermostable vaccine with broad Leptospira specificity and enhanced efficacy.This study will 1) investigate vaccine candidate diversity across leptospire species including surveying whether variants from some species exhibit adhesion preference for molecules from specific host species resulting in known host specificity and identify, whether variants from commensal (harmless) relatives lack ability to attach to host molecules, 2) use sequence diversity/conservation and differences in adhesion ability together with artificial intelligence (AI) generated structural models with in silico approaches to engineer the surface proteins to restrict host interaction which in line with recent human pathogen disease work should allow for more effective vaccines, 3) use sequence diversity together with AI generated structural models and in silico approaches to synthesise surface proteins with enhanced stability, 4) use a rodent models of disease to identify those engineered bacterial surface proteins most likely to offer protection from a range of the disease causing bacteria.Investigating BL vaccine candidates by the diverse and comprehensive methods described above, should help characterise the causal bacteria, improve understanding of the disease, substantially progress the vaccine development pipeline and/or identify novel therapeutics. Such studies are both timely and much needed to enable the prevention or even eradication of this severe, important global disease.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3390/microorganisms12020245
发表时间: 2024-02-01
期刊: MICROORGANISMS
影响因子: 4.5
作者: [Kamaruzaman,Intan Noor Aina, Staton,Gareth James, Evans,Nicholas James]
通讯作者: Evans,Nicholas James
Dissecting treponemal immune-modulation to enable disease control.
  • 批准号:
    BB/X016226/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $100.48万
  • 财政年份:
    2024
  • 负责人:
    Nicholas Evans
  • 依托单位:
MICA: Ultrasound-responsive agents for non-invasive fracture healing
  • 批准号:
    MR/X009793/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $123.72万
  • 财政年份:
    2023
  • 负责人:
    Nicholas Evans
  • 依托单位:
New Frontiers in Particle Physics, Cosmology and Gravity
  • 批准号:
    ST/T000775/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $190.95万
  • 财政年份:
    2020
  • 负责人:
    Nicholas Evans
  • 依托单位:
Bubbles to Bond Broken Bones: targeted drug delivery for fracture repair
  • 批准号:
    EP/R013594/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $57.23万
  • 财政年份:
    2018
  • 负责人:
    Nicholas Evans
  • 依托单位:
国内基金
海外基金
全细胞疫苗Cell@MnO2的乳腺癌术后免疫响应监测与放射免疫治疗研究
  • 批准号:
    QN25H220002
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    顾媛
  • 依托单位:
T-cell Receptor信号通路调控基因的表达机制分子解析
  • 批准号:
    32570839
  • 项目类别:
    面上项目
  • 资助金额:
    50.00万元
  • 批准年份:
    2025
  • 负责人:
    范高峰
  • 依托单位:
染色体外环状DNA以cell-in-cell途径促进基因横向传递和扩增的研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    15.0万元
  • 批准年份:
    2024
  • 负责人:
    王锐智
  • 依托单位:
GMFG/F-actin/cell adhesion 轴驱动 EHT 在造 血干细胞生成中的作用及机制研究
  • 批准号:
    TGY24H080011
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    李鸿鹄
  • 依托单位: